Total Funding
41
35
Total FundingVenture - Series Unknown raised
Growth Score 41 in past quarter
-29 pts
Heat Score 35 in past quarter
-16 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
118045
Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines.
John Burt: Chief Executive OfficerPast Role: Abzena, Chief Executive Officer
Nigel Davis: Founder & CBOPast Role: Medherant, Founder & CEO
About the Company
Medherant was founded by Professor David Haddleton and the University of Warwick to develop and commercialise novel transdermal drug delivery platforms. Current patch technologies have limited drug loading capabilities, making them unviable for use with many pharmaceutical products that could benefit from transdermal delivery. Creams and gels on
the other hand suffer from a lack of dose control that is critical for many drugs.
